At the BriaCell Therapeutics Corp. Annual General and Special Meeting of Shareholders for the year ended July 31, 2022, a resounding success was seen with a total of 6,663,370 Common Shares voted, representing 42.94% of the Company’s issued and outstanding Common Shares. All proposed resolutions were overwhelmingly approved, marking a major step forward for the Company’s future endeavors.
The Board of Directors has appointed MNP LLP to serve as the Company’s auditors for the upcoming year and has granted the Directors the authority to determine the compensation for the firm. This is a crucial step in ensuring the Company’s financials are accurately reported and that its stakeholders can have faith in the transparency and integrity of its reporting.
The Company is proud to announce the election of seven highly qualified and talented directors: Dr. William V. Williams, Mr. Jamieson Bondarenko, Mr. Marc Lustig, Dr. Jane A. Gross, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin E. Schmieg. Each brings a wealth of knowledge and experience to the board, and together they will work to ensure the Company’s success.
The Board of Directors is pleased to announce the approval of the Company’s cutting-edge Omnibus Equity Incentive Plan, giving employees the chance to share in the success of the Company.
The Omnibus Plan grants employees the opportunity to receive restricted share units as a reward for their hard work and dedication. We are delighted to announce the ratification of these awards, which will provide a valuable addition to the compensation of our valued team members.
The Company has proposed an amendment to its Articles that would mandate that two or more shareholders representing at least 33 1/3% of the outstanding shares entitled to vote must be present, either in person or by proxy, in order for a quorum to be constituted at any shareholder meeting. This amendment further removes the quorum exception for meetings of shareholders that follow one another.
The Company’s Omnibus Plan, having gained approval from Shareholders, is now awaiting final approval from the Toronto Stock Exchange. A report detailing the results of the Meeting’s voting on all matters will be submitted to the Company’s SEDAR profile.
About BriaCell Therapeutics Corp.
At BriaCell, we’re pioneering breakthroughs in immuno-oncology treatments and therapies to help fight cancer. Our targeted and effective approaches are revolutionizing the way we manage and treat this disease, providing hope to those affected.